Internationally Renowned Oncologist Named Physician-In-Chief At Ohio State  

Share this news item:

Contact Us

For media inquiries:
614-293-3737

To find a doctor, get a referral or for information on a clinical trial:
614-293-5066
or 800-293-5066

Search for a clinical trial

Posted: 10/26/2011

COLUMBUS, Ohio – Internationally renowned gastrointestinal oncologist Dr. Richard M. Goldberg has been named physician-in-chief at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Institute (OSUCCC-James).
 
A member and former chair of the National Cancer Institute Colorectal Task Force, Goldberg is an international leader in evaluating new agents for the treatment of colorectal cancer and researching inherited colorectal cancer syndromes. 
 
“As physician-in-chief for The OSUCCC – James, Dr. Goldberg will be instrumental in leading our preparation for and transition into the new James Cancer Hospital and Solove Research Institute, opening in 2014,” said Dr. Michael A. Caligiuri, director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute. “He will expand our infrastructure to unite researcher and clinician to bring the latest discoveries from the lab into the clinic for our patients. His expertise in gastrointestinal cancers will provide world-class prevention, detection and treatment right here at Ohio State.”
 
Goldberg will lead a medical staff of more than 100 surgical, medical and radiation oncologists, each specializing in one particular cancer and working as part of a multidisciplinary clinical team. He will assist ongoing efforts to increase the number of clinical trials available, as well as the number of patients participating in trials at Ohio State. He will help develop and implement strategies for recruiting and retaining world-class cancer experts to Ohio State. 
 
With the opening of the new 276-bed, 21-floor cancer hospital, Goldberg will aid efforts to expand local, regional and national markets and strengthen relationships with referring physicians. He will also oversee quality and safety indicators, as well as patient experience and satisfaction. 
 
“Cancer is a complicated disease,” said Goldberg.  “It requires minds from a broad spectrum of disciplines focusing their expertise and perspective on one particular form of the disease. It also requires clinicians and researchers, working together in an environment that fosters delivering the right treatment at the right time to provide the very best outcome for each patient. Ohio State is such a place. Drawing on the expertise across disciplines and throughout one of the nation’s largest public universities, Ohio State is uniquely positioned to lead the fight for a cancer-free world, and I’m excited to be a part of an amazing tradition, and an even more promising future.”
 
Goldberg will see gastrointestinal cancer patients at The James starting next month.
“We are thrilled to have Dr. Goldberg join our team,” said Dr. Tanios Bekaii-Saab, medical director of gastrointestinal oncology at OSUCCC-James.  “He will add international tenure to the already existing strength of our gastrointestinal cancer program as it continues its expansion.”
 
Goldberg comes to Ohio State from the University of North Carolina at Chapel Hill, where he was a distinguished professor of gastrointestinal cancer research and the physician-in-chief at North Carolina Cancer Hospital. He is also the chair and CEO for ARCAD US Foundation and the co-chair of the Society of Translational Oncology.
 
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 210-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S. News & World Report. 
 
# # #
 
Contact: Eileen Scahill, Medical Center Public Affairs and Media Relations, 614-293-3737, or Eileen.Scahill@osumc.edu
 
 


Tags: Cancer; Colorectal Cancer; Digestive/Gastrointestinal Cancer; Research; James Cancer Hospital; Researchers

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu